Hyaluronic acid-based conjugates for tumor-targeted drug delivery and imaging

Journal of Biomedical Nanotechnology

Volumn 10, Issue 1, 2014, Pages 17-31

  Saravanakumar, Gurusamy ^a   Deepagan, V G ^a   Jayakumar, R ^b   Park, Jae Hyung ^a  

^a Sungkyunkwan University   (South Korea)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Conjugate; Drug delivery; Hyaluronic acid; Imaging agent

Indexed keywords

ACTIVATED MACROPHAGES; BIOLOGICAL PROPERTIES; CONJUGATE; DRUG DELIVERY SYSTEM; IMAGING AGENT; RECEPTOR-MEDIATED ENDOCYTOSIS; TUMOR-TARGETED DRUG DELIVERIES; WATER SOLUBILITIES;

BIOCOMPATIBILITY; BIODEGRADATION; DRUG DELIVERY; MOLECULAR BIOLOGY; ORGANIC ACIDS;

HYALURONIC ACID;

CAMPTOTHECIN; CARBON NANOTUBE; CHITOSAN; CURCUMIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FULLERENE DERIVATIVE; GADOLINIUM CHELATE; GRAPHENE; HYALURONIC ACID; LUNG RESISTANCE PROTEIN; METHOTREXATE; MITOMYCIN; NANOPARTICLE; PACLITAXEL; POLYAMIDOAMINE; POLYETHYLENEIMINE; RETINOIC ACID; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ACUTE MONOCYTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BLADDER CANCER; BODY DISTRIBUTION; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CARCINOMATOUS PERITONITIS; CELL SURVIVAL; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CIRCULATION TIME; COLON CANCER; COLON CARCINOMA; COMPLEX FORMATION; CONJUGATE; CONJUGATION; DEACETYLATION; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; ENDOCYTOSIS; FLUORESCENCE IMAGING; GENE SILENCING; HUMAN; HYDROLYSIS; IMMUNOGENICITY; INTERNALIZATION; KNEE OSTEOARTHRITIS; LEUKEMIA CELL; LIPOPHILICITY; LUNG CARCINOMA; MACROPHAGE; MOLECULAR WEIGHT; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOPHILICITY; OVARY CANCER; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; PROMYELOCYTIC LEUKEMIA; PROSTATE CARCINOMA; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SOLUBILITY; VISCOELASTICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; HYALURONIC ACID; MOLECULAR IMAGING; NANOCONJUGATES; NEOPLASMS; POLYMERS;

EID: 84889051137     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1761     Document Type: Review

References (75)

1. J. H. Park, S. Lee, J.-H. Kim, K. Park, K. Kim, and I. C. Kwon, Polymeric nanomedicine for cancer therapy. Prog. Polym. Sci. 33, 113 (2008).
2. R. Duncan, The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347 (2003).
3. H. Ringsdorf, Structure and properties of pharmacologically active polymers. Journal of Polymer Science: Polymer Symposia 51, 135 (1975).
4. L. Lapcčik, S. De Smedt, J. Demeester, and P. Chabrecček, Hyaluronan: Preparation, structure, properties, and applications. Chem. Rev. 98, 2663 (1998).
5. B. P. Toole, Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 4, 528 (2004).
6. T. Laurent and J. Fraser, Hyaluronan. FASEB J. 6, 2397 (1992).
7. P. H. Weigel, V. C. Hascall, and M. Tammi, Hyaluronan synthases. J. Biol. Chem. 272, 13997 (1997).
8. V. M. Platt and F. C. Szoka, Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 5, 474 (2008).
9. K. Y. Choi, G. Saravanakumar, J. H. Park, and K. Park, Hyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer. Colloids and Surfaces B: Biointerfaces 99, 82 (2012).
10. C. E. Schanté, G. Zuber, C. Herlin, and T. F. Vandamme, Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications. Carbohydr. Polym. 85, 469 (2011).
11. S. Oerther, A.-C. Maurin, E. Payan, P. Hubert, F. Lapicque, N. Presle, J. Dexheimer, P. Netter, and F. Lapicque, High interaction alginate-hyaluronate associations by hyaluronate deacetylation for the preparation of efficient biomaterials. Biopolymers 54, 273 (2000).
12. P. Bulpitt and D. Aeschlimann, New strategy for chemical modification of hyaluronic acid: Preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. J. Biomed. Mater. Res. 47, 152 (1999).
13. G. Jiang, K. Park, J. Kim, K. S. Kim, and S. K. Hahn, Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol. Pharm. 6, 727 (2009).
14. Y. Luo and G. D. Prestwich, Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug. Chem. 10, 755 (1999).
15. A. Homma, H. Sato, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T. Matsuura, S. Sato, T. Tamura, Y. Higuchi, T. Watanabe, H. Kitamura, K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H. Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, and R. Suzuki, Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment. Biorg. Med. Chem. 17, 4647 (2009).
16. M. C. C. Fau-Palumbo, S. P. M. Fau-Stefanelli, M. S. S. Fau-Rassu, G. R. M. Fau-Palu, and G. Palu, Water-soluble polysaccharide-anthracycline conjugates: Biological activity. Anticancer Drug Design 7, 141 (1992).
17. H. Lee, K. Lee, and T. G. Park, Hyaluronic acid-paclitaxel conjugate micelles: Synthesis, characterization, and antitumor activity. Bioconjug. Chem. 19, 1319 (2008).
18. Y. Luo, M. R. Ziebell, and G. D. Prestwich, A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 1, 208 (2000).
19. B. Thierry, P. Kujawa, C. Tkaczyk, F. M. Winnik, L. Bilodeau, and M. Tabrizian, Delivery platform for hydrophobic drugs: Prodrug approach combined with self-assembled multilayers. J. Am. Chem. Soc. 127, 1626 (2005).
20. A. Rosato, A. Banzato, G. De Luca, D. Renier, F. Bettella, C. Pagano, G. Esposito, P. Zanovello, and P. Bassi, Hytad1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urologic Oncology-Seminars and Original Investigations 24, 207 (2006).
21. A. Banzato, S. Bobisse, M. Rondina, D. Renier, F. Bettella, G. Esposito, L. Quintieri, L. Meléndez-Alafort, U. Mazzi, P. Zanovello, and A. Rosato, A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 14, 3598 (2008).
22. I. De Stefano, A. Battaglia, G. Zannoni, M. Prisco, A. Fattorossi, D. Travaglia, S. Baroni, D. Renier, G. Scambia, C. Ferlini, and D. Gallo, Hyaluronic acid - paclitaxel: Effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother. Pharmacol. 68, 107 (2010).
23. G. Journo-Gershfeld, D. Kapp, Y. Shamay, J. Kopeéek, and A. David, Hyaluronan oligomers-hpma copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm. Res. 29, 1121 (2012).
24. Y. Luo, N. J. Bernshaw, Z.-R. Lu, J. Kopecek, and G. D. Prestwich, Targeted delivery of doxorubicin by hpma copolymer-hyaluronan bioconjugates. Pharm. Res. 19, 396 (2002).
25. E. S. Chan and B. N. Cronstein, Molecular action of methotrexate in inflammatory diseases. Arthritis Research 4, 266 (2002).
26. U. Mukesh, V. Kulkarni, R. Tushar, and R. S. Murthy, Methotrexate loaded self stabilized calcium phosphate nanoparticles: A novel inorganic carrier for intracellular drug delivery. J. Biomed. Nanotechnol. 5, 99 (2009).
27. Z. A. Khan, R. Tripathi, and B. Mishra, Methotrexate: A detailed review on drug delivery and clinical aspects. Expert Opinion on Drug Delivery 9, 151 (2012).
28. A. Homma, H. Sato, T. Tamura, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T. Matsuura, S. Sato, Y. Higuchi, T. Watanabe, H. Kitamura, K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H. Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, and R. Suzuki, Synthesis and optimization of hyaluronic acid-methotrexate conjugates to maximize benefit in the treatment of osteoarthritis. Biorg. Med. Chem. 18, 1062 (2010).
29. P. Anand, A. B. Kunnumakkara, R. A. Newman, and B. B. Aggarwal, Bioavailability of curcumin: Problems and promises. Mol. Pharm. 4, 807 (2007).
30. S. Manju and K. Sreenivasan, Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J. Colloid Interface Sci. 359, 318 (2011).
31. D. Coradini, C. Pellizzaro, G. Miglierini, M. G. Daidone, and A. Perbellini, Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line. Int. J. Cancer 81, 411 (1999).
32. D. Coradini and A. Perbellini, Hyaluronan: A suitable carrier for an histone deacetylase inhibitor in the treatment of human solid tumors. Cancer Therapy 2, 201 (2004).
33. D. Coradini, S. Zorzet, R. Rossin, I. Scarlata, C. Pellizzaro, C. Turrin, M. Bello, S. Cantoni, A. Speranza, G. Sava, U. Mazzi, and A. Perbellini, Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res. 10, 4822 (2004).
34. M. J. Vicent, F. Greco, R. I. Nicholson, A. Paul, P. C. Griffiths, and R. Duncan, Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem. Int. Ed. 44, 4061 (2005).
35. F. Greco and M. J. Vicent, Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61, 1203 (2009).
36. D. Z. Qian, M. Ren, Y. Wei, X. Wang, F. van de Geijn, C. Rasmussen, O. Nakanishi, N. Sacchi, and R. Pili, In vivo imaging of retinoic acid receptor β2 transcriptional activation by the histone deacetylase inhibitor ms-275 in retinoid-resistant prostate cancer cells. The Prostate 64, 20 (2005).
37. D. Coradini, C. Pellizzaro, I. Scarlata, S. Zorzet, C. Garrovo, G. Abolafio, A. Speranza, M. Fedeli, S. Cantoni, G. Sava, M. G. Daidone, and A. Perbellini, A novel retinoic//butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: Preliminary preclinical results. Leukemia 20, 785 (2006).
38. C. D. Novina and P. A. Sharp, The RNAi revolution. Nature 430, 161 (2004).
39. G. J. Hannon and J. J. Rossi, Unlocking the potential of the human genome with RNA interference. Nature 431, 371 (2004).
40. D. W. Pack, A. S. Hoffman, S. Pun, and P. S. Stayton, Design and development of polymers for gene delivery. Nat Rev Drug Discov 4, 581 (2005).
41. S. De Smedt, J. Demeester, and W. Hennink, Cationic polymer based gene delivery systems. Pharm. Res. 17, 113 (2000).
42. S. Mishra, P. Webster, and M. E. Davis, PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83, 97 (2004).
43. M. Hornof, M. de la Fuente, M. Hallikainen, R. H. Tammi, and A. Urtti, Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. The Journal of Gene Medicine 10, 70 (2008).
44. X. Sun, P. Ma, X. Cao, L. Ning, Y. Tian, and C. Ren, Positive hyaluronan/PEI/DNA complexes as a target-specific intracellular delivery to malignant breast cancer. Drug Deliv. 16, 357 (2009).
45. S. Asayama, M. Nogawa, Y. Takei, T. Akaike, and A. Maruyama, Synthesis of novel polyampholyte comb-type copolymers consisting of a poly(l-lysine) backbone and hyaluronic acid side chains for a DNA carrier. Bioconjug. Chem. 9, 476 (1998).
46. G. Jiang, K. Park, J. Kim, K. S. Kim, E. J. Oh, H. Kang, S.-E. Han, Y.-K. Oh, T. G. Park, and S. K. Hahn, Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA. Biopolymers 89, 635 (2008).
47. A. Saraf, M. C. Hacker, B. Sitharaman, K. J. Grande-Allen, M. A. Barry, and A. G. Mikos, Synthesis and conformational evaluation of a novel gene delivery vector for human mesenchymal stem cells. Biomacromolecules 9, 818 (2008).
48. J. Yao, Y. Fan, R. Du, J. Zhou, Y. Lu, W. Wang, J. Ren, and X. Sun, Amphoteric hyaluronic acid derivative for targeting gene delivery. Biomaterials 31, 9357 (2010).
49. S. Mahor, B. C. Dash, S. O'Connor, and A. Pandit, Mannosylated polyethyleneimine-hyaluronan nanohybrids for targeted gene delivery to macrophage-like cell lines. Bioconjug. Chem. 23, 1138 (2012).
50. T. Ito, N. Iida-Tanaka, T. Niidome, T. Kawano, K. Kubo, K. Yoshikawa, T. Sato, Z. Yang, and Y. Koyama, Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: Protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. J. Control Release 112, 382 (2006).
51. G. Liu, K. Y. Choi, A. Bhirde, M. Swierczewska, J. Yin, S. W. Lee, J. H. Park, J. I. Hong, J. Xie, G. Niu, D. O. Kiesewetter, S. Lee, and X. Chen, Sticky nanoparticles: A platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angew. Chem. Int. Ed. 51, 445 (2012).
52. M. Han, Q. Lv, X.-J. Tang, Y.-L. Hu, D.-H. Xu, F.-Z. Li, W.-Q. Liang, and J.-Q. Gao, Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J. Control Release 163, 136 (2012).
53. R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen, and Z. Zhong, Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J. Control Release 152, 2 (2011).
54. H. Mok, J. W. Park, and T. G. Park, Antisense oligodeoxynucleotide- conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition. Bioconjug. Chem. 18, 1483 (2007).
55. K. Y. Choi, S. Lee, K. Park, K. Kim, J. H. Park, I. C. Kwon, and S. Y. Jeong, Preparation and characterization of hyaluronic acid-based hydrogel nanoparticles. J. Phys. Chem. Solids 69, 1591 (2008).
56. K. Y. Choi, K. H. Min, J. H. Na, K. Choi, K. Kim, J. H. Park, I. C. Kwon, and S. Y. Jeong, Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: Synthesis, characterization, and in vivo biodistribution. J. Mater. Chem. 19, 4102 (2009).
57. G. Saravanakumar, K. Y. Choi, H. Y. Yoon, K. Kim, J. H. Park, I. C. Kwon, and K. Park, Hydrotropic hyaluronic acid conjugates: Synthesis, characterization, and implications as a carrier of paclitaxel. Int. J. Pharm. 394, 154 (2010).
58. H. Lee, C. H. Ahn, and T. G. Park, Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol. Biosci. 9, 336 (2009).
59. G. Pitarresi, F. S. Palumbo, A. Albanese, C. Fiorica, P. Picone, and G. Giammona, Self-assembled amphiphilic hyaluronic acid graft copolymers for targeted release of antitumoral drug. J. Drug Target. 18, 264 (2010).
60. A. K. Yadav, P. Mishra, S. Jain, P. Mishra, A. K. Mishra, and G. P. Agrawal, Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J. Drug Target. 16, 464 (2008).
61. K. Y. Choi, H. Chung, K. H. Min, H. Y. Yoon, K. Kim, J. H. Park, I. C. Kwon, and S. Y. Jeong, Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31, 106 (2010).
62. K. Y. Choi, H. Y. Yoon, J.-H. Kim, S. M. Bae, R.-W. Park, Y. M. Kang, I.-S. Kim, I. C. Kwon, K. Choi, S. Y. Jeong, K. Kim, and J. H. Park, Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 5, 8591 (2011).
63. S. Kim, Y. Shi, J. Y. Kim, K. Park, and J.-X. Cheng, Overcoming the barriers in micellar drug delivery: Loading efficiency. in vivo stability, and micelle-cell interaction. Expert Opinion on Drug Delivery 7, 49 (2010).
64. S.-Y. Han, H. S. Han, S. C. Lee, Y. M. Kang, I.-S. Kim, and J. H. Park, Mineralized hyaluronic acid nanoparticles as a robust drug carrier. J. Mater. Chem. 21, 7996 (2011).
65. K. K. Upadhyay, J. F. L. Meins, A. Misra, P. Voisin, V. Bouchaud, E. Ibarboure, C. Schatz, and S. Lecommandoux, Biomimetic doxorubicin loaded polymersomes from hyaluronan-block-poly(γ-benzyl glutamate) copolymers. Biomacromolecules 10, 2802 (2009).
66. K. K. Upadhyay, A. N. Bhatt, E. Castro, A. K. Mishra, K. Chuttani, B. S. Dwarakanath, C. Schatz, J.-F. Le Meins, A. Misra, and S. Lecommandoux, In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol. Biosci. 10, 503 (2010).
67. K. K. Upadhyay, A. N. Bhatt, A. K. Mishra, B. S. Dwarakanath, S. Jain, C. Schatz, J.-F. Le Meins, A. Farooque, G. Chandraiah, A. K. Jain, A. Misra, and S. Lecommandoux, The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly([gamma]-benzyl l-glutamate)-b-hyaluronan polymersomes. Biomaterials 31, 2882 (2010).
68. D.-E. Lee, A. Y. Kim, H. Y. Yoon, K. Y. Choi, I. C. Kwon, S. Y. Jeong, J. H. Park, and K. Kim, Amphiphilic hyaluronic acid-based nanoparticles for tumor-specific optical/MR dual imaging. J. Mater. Chem. 22, 10444 (2012).
69. H.-J. Cho, H. Y. Yoon, H. Koo, S.-H. Ko, J.-S. Shim, J.-H. Cho, J. H. Park, K. Kim, I. C. Kwon, and D.-D. Kim, Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. J. Control Release 162, 111 (2012).
70. H. Y. Yoon, H. Koo, K. Y. Choi, S. J. Lee, K. Kim, I. C. Kwon, J. F. Leary, K. Park, S. H. Yuk, J. H. Park, and K. Choi, Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 33, 3980 (2012).
71. K. Y. Choi, K. H. Min, H. Y. Yoon, K. Kim, J. H. Park, I. C. Kwon, K. Choi, and S. Y. Jeong, PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 32, 1880 (2011).
72. A. K. Yadav, P. Mishra, A. K. Mishra, P. Mishra, S. Jain, and G. P. Agrawal, Development and characterization of hyaluronic acid-anchored plga nanoparticulate carriers of doxorubicin. Nanomed. Nanotechnol. Biol. Med. 3, 246 (2007).
73. J. Li, M. Huo, J. Wang, J. Zhou, J. M. Mohammad, Y. Zhang, Q. Zhu, A. Y. Waddad, and Q. Zhang, Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 33, 2310 (2012).
74. M. Swierczewska, K. Y. Choi, E. L. Mertz, X. Huang, F. Zhang, L. Zhu, H. Y. Yoon, J. H. Park, A. Bhirde, S. Lee, and X. Chen, A facile, one-step nanocarbon functionalization for biomedical applications. Nano Lett. 12, 3613 (2012).
75. D. S. Kwag, K. Park, K. T. Oh, and E. S. Lee, Hyaluronated fullerenes with photoluminescent and antitumoral activity. Chem. Commun. 49, 282 (2013).